On a global scale, cancer is the second leading cause of mortality and morbidity. Gene mutation is the most common cause of cancer, but inherited genes are also a component. It is divided into lymphomas, brain tumors, carcinomas, sarcomas, and leukemias based on the type of cell it begins to form cancerous with. According to the World Health Organization (WHO), 2017, cancer is responsible for nearly one in every six deaths globally, with 70 % of cancer deaths happening in low- and middle-income nations. Furthermore, 70 % of new cases are expected to be diagnosed globally over the next two decades. The introduction of cancer vaccines has the potential to significantly reduce these figures and provide a cancer-free life for the global population.
Over the forecast period, the development of novel vaccines for the treatment of various cancers is expected to drive the growth of the global cancer vaccines market.
Manufacturers of cancer vaccines are concentrating their efforts on developing new vaccines to treat a variety of cancers. They are expected to gain a competitive advantage in the market and increase their market share as a result of this. For instance, NEC Corporation and VAXIMM AG collaborated on the development of novel neoantigen cancer vaccines in November 2019.
Get PDF Brochure with COVID19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-pdf/1209
In July 2019, Boehringer Ingelheim International GmbH announced the acquisition of AMAL Therapeutics SA, a company that uses its KISIMA technology to develop cancer immunotherapy and vaccines. The acquisition is expected to improve Boehringer’s cancer vaccine portfolio and platform.
Gilead Science Inc. in 2017, acquired Kite Pharma Inc., which is associated with the development of various types of immunotherapy and vaccines. Treos Bio also teamed up with Pharmaceutical Product Development, LLC (PPD) to perform a first-in-human clinical trial for its cancer vaccine for metastatic colorectal cancer in 2017.
Furthermore, BioNTech produced RNA vaccines to prevent cancer-related mutations. The RNA vaccine introduces cancer cells to antigen, which the immune system identifies. Scancell’s DNA vaccine, on the other hand, forces cancer cells to express two antigens – gp100 and TRP-2 – initiating a strong T cell response.
The National Cancer Institute designated the Jonsson Comprehensive Cancer Center and the Brain Tumor Center at the University of California Los Angeles (UCLA) as a Specialized Program of Research Excellence (SPORE) in 2017. The program is intended to support cancer prevention, detection, and treatment research, as well as promote collaboration among scientists from various disciplines and assist in the faster and more effective translation of fundamental research into clinical trials. National organizations are expected to support cancer vaccine research as a result of such recognition.
A high dose flu vaccine can be used to treat a person aged 54–64 years with chronic conditions such as cancer, lung disease, heart disease, and diabetes, according to a study from the University Of Pittsburgh School Of Medicine published in 2017. Clinical trials in the geriatric population are recommended for this study.
VXM01, an attenuated bacterial vaccine adjusted to express vascular endothelial growth factor receptor-2 (VEGFR2), activates cytotoxic (killer) T cells, which destroy cells in the vasculature feeding tumor and allow greater infiltration of immune cells, was also developed by Swiss Biotech in 2017. Colorectal cancer and glioblastoma are expected to benefit from this vaccine.
Imugene Limited announced in August 2017 that its anti-cancer vaccine, HER-Vaxx, for gastric cancer, had entered phase 1b/2 clinical trials, with phase 2 expected to begin soon.
The global cancer vaccines market is expected to grow due to the rising prevalence and incidence of different types of cancer.
According to the World Health Organization (WHO), around 8.8 million people died from cancer in 2015. Furthermore, tobacco-related cancers were responsible for 22% of deaths, with lung cancer accounting for 1.69 million deaths and liver cancer accounting for 788,000. Colorectal cancer, stomach cancer, and breast cancer are estimated to affect 774,000, 754,000, and 571,000 people globally, respectively. Rising prevalence of cancer is a main factor fueling the global cancer vaccines market.
Cancer is the second most common cause of death in the U.S., accounting for nearly one out of every four deaths, according to the American Cancer Society.
Global Cancers Vaccine Market Taxonomy:
By Product Type:
- Preventive Cancer Vaccines
- Therapeutic Cancer Vaccines
By Technology:
- Subunit Vaccines
- Live Attenuated Vaccines
- Conjugate Vaccines
- Inactivated Vaccines
- Recombinant Vector Vaccines
- Viral Vector and DNA Cancer Vaccines
- Others
By Application:
- Cervical cancer
- Prostate cancer
- Others
Major Players Are: Astrazeneca Plc. (Medimmune, LLC.), Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur, Aduro BioTech Inc., Sanpower Group, Astellas Pharma Inc., CSL Limited, Pfizer Inc., and Serum Institute of India Pvt. Ltd.
Purchase This Premium Report Here With Discounted Price (Flat US $2000 Off) – https://www.coherentmarketinsights.com/promo/buynow/1209
Reasons to Purchase this Report
• Current and future of global Cancer Vaccines market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837